A single centre, retrospective cohort study assessing effectiveness of Fidaxomicin versus Oral Vancomycin in the treatment of Recurrent Clostridioides difficile
Latest Information Update: 17 Dec 2020
Price :
$35 *
At a glance
- Drugs Fidaxomicin (Primary) ; Vancomycin (Primary)
- Indications Clostridium difficile infections
- Focus Therapeutic Use
- 17 Dec 2020 New trial record
- 25 Oct 2020 Results presented at the IDWeek 2020